ZB
AUPH icon

Zions Bancorporation’s Aurinia Pharmaceuticals AUPH Stock Holding History

Zions Bancorporation’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-600
Closed -$4.4K – 863
2024
Q3 		$4.4K Hold
600
– – ﹤0.01% 729
2024
Q2 		$3.43K Hold
600
– – ﹤0.01% 793
2024
Q1 		$3.01K Hold
600
– – ﹤0.01% 808
2023
Q4 		$5.39K Hold
600
– – ﹤0.01% 740
2023
Q3 		$4.66K Hold
600
– – ﹤0.01% 734
2023
Q2 		$5.81K Hold
600
– – ﹤0.01% 711
2023
Q1 		$6.58K Hold
600
– – ﹤0.01% 704
2022
Q4 		$2.59K Hold
600
– – ﹤0.01% 930
2022
Q3 		$5K Hold
600
– – ﹤0.01% 769
2022
Q2 		$6K Hold
600
– – ﹤0.01% 810
2022
Q1 		$7K Hold
600
– – ﹤0.01% 880
2021
Q4 		$14K Hold
600
– – ﹤0.01% 687
2021
Q3 		$13K Hold
600
– – ﹤0.01% 676
2021
Q2 		$8K Hold
600
– – ﹤0.01% 753
2021
Q1 		$8K Hold
600
– – ﹤0.01% 736
2020
Q4 		$8K Hold
600
– – ﹤0.01% 713
2020
Q3 		$9K Hold
600
– – ﹤0.01% 680
2020
Q2 		$10K Hold
600
– – ﹤0.01% 624
2020
Q1 		$9K Buy
+600
New +$10.6K ﹤0.01% 596

Other funds holding AUPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Zions Bancorporation's AUPH Position: Q4 2024 in Review

Zions Bancorporation sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2024, closing a stake of 600 shares — an estimated $4.4K sold.

Zions Bancorporation first reported a position in AUPH in Q1 2020 and held it in 19 quarters. The position peaked at $14K in Q4 2021. 200 funds tracked by Wall St. Rank hold AUPH as of Q4 2024.

  • Zions Bancorporation reported no remaining Aurinia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Zions Bancorporation sold 600 Aurinia Pharmaceuticals shares in Q4 2024, an estimated $4.4K.
  • Zions Bancorporation first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 19 quarters.
  • Zions Bancorporation's Aurinia Pharmaceuticals position peaked at $14K in Q4 2021.
  • 200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2024.

Based on Zions Bancorporation's 13F filing for Q4 2024, filed 11 Feb 2025.